Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

915 questions in 93 reviews · Emergency and Critical Care

current versions

No studies 141 · 15.4%Ungraded 22 · 2.4%Very low 216 · 23.6%Low 272 · 29.7%Moderate 188 · 20.5%High 76 · 8.3%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Internal jugular vs subclavian insertion: long‐term catheterization Late mechanical complications · cancer patients Central venous access sites for the prevention of venous thrombosis, stenosis and infection (2012) · Cochrane	RR 1.67 [0.41, 6.79]	2 studies · 468 participants	Low
Femoral vs subclavian insertion: short‐term catheterization Catheter‐related infectious complications ‐ Catheter colonization · critically ill patients Central venous access sites for the prevention of venous thrombosis, stenosis and infection (2012) · Cochrane	RR 6.43 [1.95, 21.21]	1 study · 270 participants	High
Femoral vs subclavian insertion: short‐term catheterization Catheter‐related infectious complications ‐ Catheter‐related bloodstream infection · critically ill patients Central venous access sites for the prevention of venous thrombosis, stenosis and infection (2012) · Cochrane	RR 2.03 [0.19, 22.12]	1 study · 270 participants	High
Femoral vs subclavian insertion: short‐term catheterization Catheter‐related thrombotic complications · critically ill patients Central venous access sites for the prevention of venous thrombosis, stenosis and infection (2012) · Cochrane	RR 11.53 [2.8, 47.52]	1 study · 223 participants	High
Human recombinant activated protein C vs placebo 28‐Day all‐cause mortality (adult and paediatric patients) · patients with severe sepsis or septic shock Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients (2012) · Cochrane	RR 1 [0.86, 1.16]	6 studies · 6781 participants	Moderate
Human recombinant activated protein C vs placebo In‐hospital mortality (adult and paediatric patients) · patients with severe sepsis or septic shock Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients (2012) · Cochrane	RR 1.04 [0.94, 1.15]	5 studies · 4307 participants	Moderate
Human recombinant activated protein C vs placebo Serious bleeding events in adult and paediatric patients (days 0 to 28) · patients with severe sepsis or septic shock Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients (2012) · Cochrane	RR 1.45 [1.08, 1.94]	6 studies · 6767 participants	Moderate
Human recombinant activated protein C vs placebo Serious adverse events (adult and paediatric patients) · patients with severe sepsis or septic shock Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients (2012) · Cochrane	RR 1.04 [0.92, 1.18]	5 studies · 6636 participants	Moderate
Intervention NR Need for second recompression Simple count · patients with decompression illness Recompression and adjunctive therapy for decompression illness (2012) · Cochrane	RR 0.64 [0.46, 0.86]	1 study · 180 participants	High
Intervention NR Mortality 30‐day · Adult patients with SIRS or sepsis N‐acetylcysteine for sepsis and systemic inflammatory response in adults (2012) · Cochrane	RR 1.07 [0.8, 1.43]	11 studies · 930 participants	Moderate
Intervention NR Length of stay on the intensive care unit (days) · Adult patients with SIRS or sepsis N‐acetylcysteine for sepsis and systemic inflammatory response in adults (2012) · Cochrane	no estimate extracted	19 studies · 1309 participants	Moderate
Intervention NR Duration of mechanical ventilation (days) · Adult patients with SIRS or sepsis N‐acetylcysteine for sepsis and systemic inflammatory response in adults (2012) · Cochrane	no estimate extracted	9 studies · 423 participants	Moderate
Intervention NR Incidence of new organ failure · Adult patients with SIRS or sepsis N‐acetylcysteine for sepsis and systemic inflammatory response in adults (2012) · Cochrane	RR 1.01 [0.8, 1.27]	12 studies · 1224 participants	Moderate
Urokinase (any strength) vs placebo Restored patency · patients with occluded central venous catheter Interventions for restoring patency of occluded central venous catheter lumens (2012) · Cochrane	RR 2.09 [1.47, 2.95]	2 studies · 287 participants	Low
Urokinase (any strength) vs placebo Adverse effects · patients with occluded central venous catheter Interventions for restoring patency of occluded central venous catheter lumens (2012) · Cochrane	RR 2.88 [0.38, 21.93]	1 study · 72 participants	Very low